Meeting
2018 ASCO Annual Meeting
Phase 1b study of selinexor, a first in class selective inhibitor of nuclear export (SINE) compound, in combination with doxorubicin in patients (pts) with locally advanced or metastatic soft tissue sarcoma (STS).
Authors
Eoghan Ruadh Malone
Princess Margaret Cancer Centre, Toronto, ON, Canada
Eoghan Ruadh Malone , Esmail al-Ezzi , Abha A. Gupta , Pernille Pedersen , Dagmara Kolodziejczyk , Ragitha Ellencherry , Oulu Zhu , Albiruni Ryan Abdul Razak , Jeremy Howard Lewin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT03042819
Citation
J Clin Oncol 36, 2018 (suppl; abstr 11562)
DOI
10.1200/JCO.2018.36.15_suppl.11562
Abstract #
11562
Poster Bd #
307
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase 1b study of selinexor, a first-in-class selective inhibitor of nuclear export (SINE) compound, in combination with doxorubicin in patients (pts) with locally advanced or metastatic soft tissue sarcoma (STS).
First Author: Eoghan Ruadh Malone
Poster
2020 ASCO Virtual Scientific Program
A pilot study evaluating the safety, tolerability, and efficacy of doxorubicin and pembrolizumab in patients with metastatic or unresectable soft tissue sarcoma.
First Author: Michael B. Livingston
Poster
2019 ASCO Annual Meeting
CBT-1 in combination with doxorubicin in patients with metastatic, unresectable sarcomas who previously progressed on doxorubicin.
First Author: Gregory Michael Cote
Poster
2017 ASCO Annual Meeting
Administration of aldoxorubicin and 14 days continuous infusion of ifosfamide/mesna in metastatic or locally advanced sarcomas.
First Author: Frederick C. Eilber